Alaunos reports Q4 2022 net loss $9.2M, cash $53M; TCR library expanded

Alaunos Therapeutics, Inc.

Net loss $9.2M in Q4 2022 ($0.04/share) vs $11.8M ($0.05) prior year; full year loss $37.7M.
Cash and restricted cash $53.0M; expects to fund operations into Q4 2023.
Expanded TCR library with two new TCRs, doubling potential addressable market; improving patient match rate from 5% to 10%.
Transitioned to cryopreserved cell product, reducing manufacturing time from 30 to 26 days (13% decrease).
Phase 2 readiness targeted in 2023; interim data on multiple patients expected mid-2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alaunos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 7, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its fourth quarter and full year 2022 financial results.

View on SEC.gov

Browse all earnings releases →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-062072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.